LIMK2 (pT505) Antibody

LIMK2 (pT505) Antibody is a Rabbit Polyclonal antibody against LIMK2 (pT505). There are approximately 40 known eukaryotic LIM proteins, so named for the LIM domains they contain. LIM domains are highly conserved cysteine-rich structures containing 2 zinc fingers. Although zinc fingers usually function by binding to DNA or RNA, the LIM motif probably mediates protein-protein interactions. LIM kinase-1 and LIM kinase-2 belong to a small subfamily with a unique combination of 2 N-terminal LIM motifs and a C-terminal protein kinase domain. The protein encoded by this gene is phosphorylated and activated by ROCK, a downstream effector of Rho, and the encoded protein, in turn, phosphorylates cofilin, inhibiting its actin-depolymerizing activity. It is thought that this pathway contributes to Rho-induced reorganization of the actin cytoskeleton. At least three transcript variants encoding different isoforms have been found for this gene.

Target	LIMK2 (pT505)
Clonality	Polyclonal
Reactivity	Human, Mouse, Rat
Tested Applications	WB, IF/ICC
Host	Rabbit
Recommended dilutions	WB: 1/500 - 1/2000, IF/ICC: 1/100 - 1/200. Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Immunogen	A phospho specific peptide corresponding to residues surrounding T505 of human LIMK2
Isotype	IgG
Form	Liquid
Purification	Purified by affinity chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC	P53671 (UniProt, ExPASy)
UniProt Secondary AC	A8K6H5, Q7KZ80, Q7L3H5, Q96E10, Q99464, Q9UFU0
UniProt Entry Name	LIMK2_HUMAN
Gene Symbol	LIMK2
GeneID	3985
KEGG	hsa:3985
String	9606.ENSP00000339916
Molecular Weight	Calculated MW: 72 kDa Observed MW: 72 kDa
Buffer	PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol.
Concentration	> 0.2 mg/ml
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.

Research Articles on LIMK2 (pT505)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue